Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

692 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock.
Barrett JE, Herzog C, Kim YN, Bartlett TE, Jones A, Evans I, Cibula D, Zikan M, Bjørge L, Harbeck N, Colombo N, Howell SJ, Rådestad AF, Gemzell-Danielsson K, Widschwendter M. Barrett JE, et al. Among authors: harbeck n. Genome Biol. 2022 Feb 22;23(1):52. doi: 10.1186/s13059-022-02603-3. Genome Biol. 2022. PMID: 35189945 Free PMC article.
Epigenome-based cancer risk prediction: rationale, opportunities and challenges.
Widschwendter M, Jones A, Evans I, Reisel D, Dillner J, Sundström K, Steyerberg EW, Vergouwe Y, Wegwarth O, Rebitschek FG, Siebert U, Sroczynski G, de Beaufort ID, Bolt I, Cibula D, Zikan M, Bjørge L, Colombo N, Harbeck N, Dudbridge F, Tasse AM, Knoppers BM, Joly Y, Teschendorff AE, Pashayan N; FORECEE (4C) Consortium. Widschwendter M, et al. Among authors: harbeck n. Nat Rev Clin Oncol. 2018 May;15(5):292-309. doi: 10.1038/nrclinonc.2018.30. Epub 2018 Feb 27. Nat Rev Clin Oncol. 2018. PMID: 29485132 Review.
The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples.
Barrett JE, Herzog C, Jones A, Leavy OC, Evans I, Knapp S, Reisel D, Nazarenko T, Kim YN, Franchi D, Ryan A, Franks J, Bjørge L, Zikan M, Cibula D, Harbeck N, Colombo N, Dudbridge F, Jones L, Sundström K, Dillner J, Rådestad AF, Gemzell-Danielsson K, Pashayan N, Widschwendter M. Barrett JE, et al. Among authors: harbeck n. Nat Commun. 2022 Feb 1;13(1):449. doi: 10.1038/s41467-021-27918-w. Nat Commun. 2022. PMID: 35105882 Free PMC article.
Author Correction: Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock.
Barrett JJE, Herzog C, Kim YN, Bartlett TE, Jones A, Evans I, Cibula D, Zikan M, Bjørge L, Harbeck N, Colombo N, Howell SJ, Rådestad AF, Gemzell-Danielsson K, Widschwendter M. Barrett JJE, et al. Among authors: harbeck n. Genome Biol. 2022 Jun 29;23(1):142. doi: 10.1186/s13059-022-02704-z. Genome Biol. 2022. PMID: 35768851 Free PMC article. No abstract available.
Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker.
Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, Betz B, Hellebrand H, Engert S, Seitz S, Kreutzfeld R, Sasaki T, Arnold N, Schmutzler R, Kiechle M, Niederacher D, Harbeck N, Dahl E, Meindl A. Sadr-Nabavi A, et al. Among authors: harbeck n. Int J Cancer. 2009 Apr 1;124(7):1727-35. doi: 10.1002/ijc.24108. Int J Cancer. 2009. PMID: 19115204 Free article.
Angiogenesis inhibitors in the management of breast cancer.
Bossung V, Harbeck N. Bossung V, et al. Among authors: harbeck n. Curr Opin Obstet Gynecol. 2010 Feb;22(1):79-86. doi: 10.1097/GCO.0b013e328334e462. Curr Opin Obstet Gynecol. 2010. PMID: 19952746 Review.
Breast cancer.
Harbeck N, Gnant M. Harbeck N, et al. Lancet. 2017 Mar 18;389(10074):1134-1150. doi: 10.1016/S0140-6736(16)31891-8. Epub 2016 Nov 17. Lancet. 2017. PMID: 27865536 Review.
692 results